Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Turning Point Therapeutics, Inc. (TPTX)
|
Add to portfolio |
|
|
|
| Price: |
$48.74
| | Metrics |
| OS: |
49.7
|
M
| |
-34
|
% ROE
|
| Market cap: |
$2.42
|
B
| |
-51
|
% ROIC
|
|
Net cash:
|
$310
|
M
| |
$6.23
|
per share
|
|
EV:
|
$2.11
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($307)
|
M
| |
|
|
| EPS |
($6.18)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 30.8 | 30.8 | 25.0 | 25.0 | 0.0 | 26.5 | 16.9 |
| Revenue growth | 23.3% | 23.3% | | | -100.0% | 57.1% | |
| Cost of goods sold | 0.0 | 193.0 | 0.0 | 113.4 | 0.0 | 0.0 | 0.0 |
| Gross profit | 30.8 | -162.2 | 25.0 | -88.4 | 0.0 | 26.5 | 16.9 |
| Gross margin | 100.0% | -526.0% | 100.0% | -353.6% | | 100.0% | 100.0% |
| Selling, general and administrative | 268.8 | | 186.8 | | 77.7 | | |
| Research and development | | | | | | 21.1 | 15.2 |
| General and administrative | | 75.9 | | 73.4 | | 4.6 | 1.5 |
| EBIT | -238.0 | -238.0 | -161.8 | -161.8 | 0.0 | -25.6 | -16.7 |
| EBIT margin | -772.0% | -772.0% | -647.3% | -647.3% | | -96.8% | -99.2% |
| Pre-tax income | -236.6 | -236.6 | -157.3 | -157.3 | -72.1 | -24.8 | -16.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -236.6 | -236.6 | -157.3 | -157.3 | -72.1 | -24.8 | -16.6 |
| Net margin | -767.3% | -767.3% | -629.2% | -629.2% | | -93.5% | -98.4% |
| |
| Diluted EPS | ($4.80) | ($4.80) | ($3.85) | ($3.85) | ($2.99) | ($7.31) | ($4.97) |
| Shares outstanding (diluted) | 49.3 | 49.3 | 40.8 | 40.8 | 24.1 | 3.4 | 3.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|